Want to see EWTX full AI Analyst Report?
EWTX Stock Chart & Stats
$40.84
$1.55(3.95%)
At close: 4:00 PM EDT
$40.84
$1.55(3.95%)
Day’s Range― - ―
52-Week Range$13.69 - $48.40
Previous Close$40.84
Volume1.03M
Average Volume (3M)1.37M
Market Cap
$4.70B
Enterprise Value$3.92K
Total Cash (Recent Filing)$460.71M
Total Debt (Recent Filing)$3.59M
Price to Earnings (P/E)―
Beta1.90
Next Earnings
Nov 05, 2026EPS Estimate
-0.53Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.85
Shares Outstanding108,604,126
10 Day Avg. Volume859,282
30 Day Avg. Volume1,366,719
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)4.89
Price to Sales (P/S)0.00
P/FCF Ratio-17.76
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$51.18Price Target Upside25.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.05
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strengthened Balance Sheet After Asset SaleThe sevasemten sale provides a material cash infusion and raises pro forma liquidity, materially reducing refinancing and interest-rate risks. This durable funding improves the company's ability to fully finance EDG-7500 through potential approval and to advance its cardiovascular pipeline without near-term capital raises.
Focused Cardiovascular Strategy With Lead AssetsShifting to a concentrated cardiology portfolio around EDG-7500 and EDG-15400 creates strategic clarity and allows concentrated R&D spend. Focusing resources on fewer, higher-potential assets can accelerate clinical and regulatory progress and improve odds of achieving sustainable, commercial-stage value over the medium term.
Low Leverage And Minimal DebtExtremely low leverage and minimal outstanding debt reduce financing pressure and interest expense risk. This structural balance-sheet strength provides flexibility to fund clinical programs, pursue partnerships, and withstand trial timelines without the same refinancing constraints faced by more highly leveraged peers.
Bears Say
Pre-commercial With Zero RevenueAs a pre-revenue biotech, the company lacks product sales and is highly dependent on financing, partnerships, or milestone receipts. Persistent and growing operating losses mean long-term value hinges entirely on clinical success and approvals; trial setbacks would materially impair future cash flow prospects.
Large Negative Operating And Free Cash FlowSustained negative operating and free cash flow reflect high R&D and clinical spend. Even with recent proceeds, ongoing burn can erode runway over time, creating a structural need for milestone receipts, partnerships, or further financing that could dilute shareholders or constrain strategic autonomy if trial timelines lengthen.
Sale Removes Late-stage Muscular Dystrophy AssetDivesting sevasemten and the muscular dystrophy business reduces pipeline diversification and forfeits a late-stage asset with orphan designations. This concentrates clinical and commercial risk on the cardiovascular portfolio and eliminates a potential near-term revenue stream if the neuromuscular asset had succeeded.
Edgewise Therapeutics News
EWTX FAQ
What was Edgewise Therapeutics, Inc.’s price range in the past 12 months?
Edgewise Therapeutics, Inc. lowest stock price was $13.69 and its highest was $48.40 in the past 12 months.
What is Edgewise Therapeutics, Inc.’s market cap?
Edgewise Therapeutics, Inc.’s market cap is $4.70B.
When is Edgewise Therapeutics, Inc.’s upcoming earnings report date?
Edgewise Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Edgewise Therapeutics, Inc.’s earnings last quarter?
Edgewise Therapeutics, Inc. released its earnings results on Aug 06, 2026. The company reported -$0.53 earnings per share for the quarter, missing the consensus estimate of -$0.468 by -$0.062.
Is Edgewise Therapeutics, Inc. overvalued?
According to Wall Street analysts Edgewise Therapeutics, Inc.’s price is currently Undervalued.
Does Edgewise Therapeutics, Inc. pay dividends?
Edgewise Therapeutics, Inc. does not currently pay dividends.
What is Edgewise Therapeutics, Inc.’s EPS estimate?
Edgewise Therapeutics, Inc.’s EPS estimate is -0.53.
How many shares outstanding does Edgewise Therapeutics, Inc. have?
Edgewise Therapeutics, Inc. has 108,604,126 shares outstanding.
What happened to Edgewise Therapeutics, Inc.’s price movement after its last earnings report?
Edgewise Therapeutics, Inc. reported an EPS of -$0.53 in its last earnings report, missing expectations of -$0.468. Following the earnings report the stock price went down -1.267%.
Which hedge fund is a major shareholder of Edgewise Therapeutics, Inc.?
Currently, no hedge funds are holding shares in EWTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edgewise Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$51.18 (25.32% Upside)
$51.18 (25.32% Upside)
Blogger Sentiment
Bullish
EWTX Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $7.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
179.15%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-21.79%
Trailing 12-Months
Company Description
Edgewise Therapeutics, Inc.
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.
EWTX Stock 12 Month Forecast
Average Price Target
$51.18
▲(25.32% Upside)
Technical Analysis
Viridian Therapeutics
―
Pharvaris
―
Vera Therapeutics
―
Janux Therapeutics Inc
―
Biohaven Ltd.
―
Ownership Overview
0.59% Insiders
13.77% Mutual Funds
66.11% Other Institutional Investors
9.84% Public Companies and
Individual Investors